EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Effectiveness and safety of caspofungin for the treatment of candidemia in critically ill patients with obesity: A multicenter retrospective cohort study

Aisha Alharbi iD, Khalid Al Sulaiman iD, Nader Damfu, Shuroug A Alowais, Sultan Alotaibi, Yazed Saleh Alsowaida, Manal A Aljohani, Nisrin Bifari, Fahad Alshammari, Mohammed Asiri, Imtinan A Almasoudi, Marwah Almuzaini und 12 weitere

Medical Mycology · 2025

DOI: 10.1093/mmy/myaf093 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Medical Mycology, 2025. Verfasst von Aisha Alharbi und 23 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs (MNGHA), Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Caspofungin, Antifungal Agents, Obesity, Candidemia. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the limited evidence on the optimal caspofungin dose for patients with obesity and candidemia, this study aims to evaluate the clinical outcomes of the standard caspofungin dose in critically ill patients with obesity and candidemia. A multicenter, retrospective cohort study was conducted in three tertiary care hospitals in Saudi Arabia. Eligible critically ill patients with confirmed candidemia who received standard dose of caspofungin were stratified according to their Body Mass Index (BMI) at the time of caspofungin initiation into two groups: control (BMI: 18–29.9 kg/m2) or obese (BMI: ≥30 kg/m2). The primary outcome was the incidence of clinical success. All other outcomes were considered secondary. The significance level was set at a P-value of <.05, and statistical analysis was conducted using SAS 9.4 software. A total of 108 patients were included; forty-six (42.6%) were obese. There were no significant differences in terms of clinical success between the groups (aOR, 1.38; 95% CI, 0.54–3.54; P = .50). Microbiological success rate was numerically higher in the control group compared to obese patients (83.9% vs. 69.6%; P = .07); notably, the difference was statistically significant in the regression analysis (aOR, 3.40; 95% CI, 1.040–11.099; P = .04). No significant differences were observed in other outcomes, including time for microbiological success, treatment failure, infection recurrence within 90 days, mortality, and length of stay. In conclusion, patients with obesity had similar clinical success to control group; however, a lower microbiological success rate was observed in patients with obesity. Further research is needed to explore long-term implications of caspofungin therapy in obese patients with candidemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CaspofunginAntifungal AgentsObesityCandidemiaHumansRetrospective StudiesMaleFemaleCritical IllnessMiddle AgedTreatment OutcomeAdultAgedSaudi ArabiaTertiary Care CentersBody Mass Index

Stichwörter der Autor:innen

candidemiacaspofunginclinical successechinocandinmicrobiological successobesity

Substanzen

CaspofunginAntifungal Agents

Autor:innen und Institutionen

  • Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs (MNGHA), Jeddah, Saudi Arabia.
  • King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
  • King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  • Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
  • College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

ORCID-Profile: Aisha Alharbi, Khalid Al Sulaiman

Zitieren

APA

Alharbi, A., Al Sulaiman, K., Damfu, N., Alowais, S. A., Alotaibi, S., Alsowaida, Y. S., Aljohani, M. A., Bifari, N., Alshammari, F., Asiri, M., Almasoudi, I. A., Almuzaini, M., Alqurashi, A. F., Alobathani, S. K., Almodyan, E. J., Almutairy, R., Aldhafeeri, M., Alshehri, R. A., Alghamdi, S. S., …, & Aljuhani, O. (2025). Effectiveness and safety of caspofungin for the treatment of candidemia in critically ill patients with obesity: A multicenter retrospective cohort study. Medical Mycology. https://doi.org/10.1093/mmy/myaf093

Vancouver

Alharbi A, Al Sulaiman K, Damfu N, Alowais SA, Alotaibi S, Alsowaida YS, et al. Effectiveness and safety of caspofungin for the treatment of candidemia in critically ill patients with obesity: A multicenter retrospective cohort study. Medical Mycology. 2025. doi:10.1093/mmy/myaf093

BibTeX
@article{Alharbi2025,
  author = {Alharbi, Aisha and Al Sulaiman, Khalid and Damfu, Nader and Alowais, Shuroug A and Alotaibi, Sultan and Alsowaida, Yazed Saleh and Aljohani, Manal A and Bifari, Nisrin and Alshammari, Fahad and Asiri, Mohammed and Almasoudi, Imtinan A and Almuzaini, Marwah and Alqurashi, Ashwaq F and Alobathani, Seba K and Almodyan, Entisar J and Almutairy, Reem and Aldhafeeri, Maha and Alshehri, Raghad A and Alghamdi, Safiah Sowaid and Alhammad, Mohamed A and Aljuhani, Atheer Mohammad and Alandas, Norah and Alotaibi, Samar and Aljuhani, Ohoud},
  title = {Effectiveness and safety of caspofungin for the treatment of candidemia in critically ill patients with obesity: A multicenter retrospective cohort study},
  journal = {Medical Mycology},
  year = {2025},
  doi = {10.1093/mmy/myaf093}
}
Kostenlos starten →